

Not for release, publication or distribution in the United States, Australia, Canada or Japan.



NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL, OTHER RESTRICTIONS ARE APPLICABLE.
PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS INVESTOR RELATIONS NEWS.

Investor Relations News

Evonik shares successfully listed on the stock exchange

- **Trading in the shares has started**

Essen, April 25, 2013. Following the successful placements by RAG Foundation and funds advised by CVC Capital Partners of a total of c. 67.4 million shares in Evonik Industries AG with institutional investors in Germany and abroad, trading of the company's shares commenced today on the Frankfurt and Luxembourg stock exchanges. A total of 466 million Evonik shares can now be traded on the stock exchanges. The free float currently amounts to c. 14.5 percent of the total shares in the company. Evonik resumed preparations for its planned stock market listing in late February 2013; the uncertain stock market conditions had prevented a listing in 2012.

Werner Müller, Chairman of the Executive Board of RAG Foundation, commented: "I am delighted that, together with CVC, we have brought Evonik to the market within this short timeframe. Thanks to the good team at Evonik, our chosen route proved successful and achieved a respectable outcome."

Christian Wildmoser, partner at CVC, added: "After four-and-a-half years of close and trustful collaboration with RAG Foundation, we are pleased that today we have successfully listed Evonik—one of the leading specialty chemicals companies—on the stock market. We are proud to have played a part in this decisive step in the company's history."

Klaus Engel, Chairman of Evonik's Executive Board, commented: "Today's stock exchange listing was made possible by a joint act of strength: on the one hand, our owners' clear determination to finally press ahead with a stock market listing, and on the other, the good business performance that we as a company have achieved in recent years. We have systematically driven forward Evonik's focus on profitable, high-growth specialty chemicals. Today is a good day for the company and for the German stock market."

Not for release, publication or distribution in the United States, Australia, Canada or Japan.

Evonik is one of the world's leading specialty chemicals companies and has a balanced portfolio. Around 80 percent of sales come from market leading positions, which it intends to expand systematically. The company concentrates on high-growth megatrends—especially health, nutrition, resource efficiency and globalization.

The prospectus for the listing of Evonik shares in the regulated market (Prime Standard) of the Frankfurt Stock Exchange and the regulated market of the Luxembourg Stock Exchange was approved by the German Federal Financial Supervisory Authority (BaFin), was published on the Evonik website on April 22, 2013 and is available for download under the link www.evonik.de/listing. A print copy of the prospectus is available free of charge from Evonik Industries AG, Rellinghauser Straße 1-11, 45128 Essen.

About RAG Foundation

RAG Foundation is a civil-law foundation established in 2007. Its purpose is to build up Foundation assets by 2018 in order to fund long-term liabilities in German coal mining from 2019 onwards. Under the Foundation's Statutes, this objective is to be achieved by means of an initial public offering of Evonik Industries AG.

For further information on the RAG Foundation, please see <http://www.rag-stiftung.de/en/>

RAG Foundation press contact:
Barbara Müller (Acting Press Officer)
Evonik Industries AG
Tel. +49-201-177-3423
E-Mail: barbara.mueller@evonik.com

About CVC Capital Partners

CVC is one of the world's leading private equity and investment advisory firms. Founded in 1981, CVC today has a network of 21 offices and 280 employees throughout Europe, Asia and the US. To date, CVC has secured commitments of more than US\$44bn in funds and completed more than 290 investments. CVC is currently invested in over 60 companies globally, which in total are employing over 400,000 employees and generating sales of over US\$130bn.

CVC is present in Germany since 1986. The investment portfolio in the German-speaking region currently comprises three companies in Germany (Evonik, Flint Group, ista) and one in Switzerland (Sunrise). In total these companies have more than 50,000 employees and generate sales of more than €18bn.

For further information, please visit www.cvc.com

Michael Iltschev
Hering Schuppener Consulting
Tel. +49-69-921874-49
Mobil: +49-151-16231325
E-Mail: miltschev@heringschuppener.com

Dr. Phoebe Kebbel
Hering Schuppener Consulting
Tel. +49-69-921874-77
Mobil: +49-173-2862110
E-Mail: pkebbel@heringschuppener.com

Not for release, publication or distribution in the United States, Australia, Canada or Japan.

About Evonik Industries AG:

Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik's corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.

Evonik is active in over 100 countries around the world. In fiscal 2012 more than 33,000 employees generated sales of around €13.6bn and an operating profit (adjusted EBITDA) of about €2.6bn.

Evonik Industries AG:

Tim Lange

Head of Investor Relations

Tel. +49-201-177-3150

E-Mail: tim.lange@evonik.com

Disclaimer:

These materials may not be published, distributed or transmitted in the United States, Canada, Australia or Japan. These materials do not constitute an offer of securities for sale or a solicitation of an offer to purchase securities (the "Shares") of Evonik Industries AG (the "Company") in the United States, Germany or any other jurisdiction. The Shares of the Company may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "Securities Act"). The Shares of the Company have not been, and will not be, registered under the Securities Act.

This publication constitutes neither an offer to sell nor a solicitation to buy securities. There will be no public offer of securities of the Company.

In the United Kingdom, this document is only being distributed to and is only directed at persons who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Order") or (ii) are persons falling within Article 49(2)(a) to (d) of the Order (high net worth companies, unincorporated associations, etc.) (all such persons together being referred to as "Relevant Persons"). This document is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

In so far as forecasts or expectations are expressed in this Investor Relations News or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.